High levels of BTMPS detected in fentanyl, raising health concerns
A UCLA research team has found that drugs being sold as fentanyl contain high amounts of the industrial chemical ...
News Medical on MSN4d
Common stimulant treatment for binge eating disorder shows mixed results
Patients taking a commonly used stimulant for the treatment of binge eating disorder experienced mixed results, according to ...
‘There has never been a more dangerous time to take drugs’: the rising global threat of nitazenes and synthetic opioids
Unlike opium, nitazenes and other synthetic opioids can be produced anywhere in the world using precursor chemicals that are often uncontrolled.
StudyFinds on MSN5d
Journavx: What to know about new FDA-approved non-opioid pain medication
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
EurekAlert!1d
Researchers find high levels of the industrial chemical BTMPS in fentanyl
A research team has found that drugs being sold as fentanyl contain high amounts of the industrial chemical bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate, or BTMPS. This new substance of concern ...
guardian.co.tt4d
New stimulant drug a concern across region
JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...
Monthly Prescribing Reference5d
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Nature4d
Drug development articles from across Nature Portfolio
Drug development describes the process of developing a new drug that effectively targets a specific weakness in a cell. This process involves specific pre-clinical development and testing ...
BioSpace5d
GH’s Inhaled Psychedelic Succeeds in Mid-Stage Depression Trial
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...